Supervisors info:
Σ. Θεοχάρης, Καθηγητής, Ιατρική Σχολή, Ε.Κ.Π.Α.
Ν. Καβαντζάς, Καθηγητής, Ιατρική Σχολή, Ε.Κ.Π.Α.
Κ. Γιαγκίνης, Επ. Καθηγητής, Τμ. Επιστήμης Τροφίμων και Διατροφής, Πανεπιστήμιο Αιγαίου
Summary:
Breast cancer constitutes a complicated and heterogenic disease in such a degree so as to be considered as a group of different entities, where each of them characterized by different clinical, histopathological, genetics features as well different therapy response, recurrence risk and biological behavior. Despite the heterogenicity, breast cancer incidences are classified according tumor size, differentiation degree, lymph node metastases and blood and lymphvessels infiltration.
Recent years, the point of view about the complication and the heterogenity of the disease, and the requirement for personalized therapy is uprated by the application of molecular biology techniques which detect a large number of gene presence, absence, induced or/and reduced expression in breast cancer tumors. Routinelly, immunohistochemical expression of ER, PR, c-erbB-2, Ki67 is used for the prediction of the disease and therapy planning. However, the reveal of new molecules like FXR contributes to the deeper unerstanding of carcinogenesis mechanism in breast but also to use FXR ligands in new therapy strategies.
In the present study, the immunohistochemical expression of the FXR in 150 tumors with invasive breast cancer was analysed. The relationship between FXR expression and different histopathological parameters is a strong indication that FXR as predictive marker, favourable for the overall survival of the patient could be used in the future.
Keywords:
Breast cancer, FXR, Immunohistochemistry, Clinicopathological parameters, Prognosis
